SCHEMBL2199582

SCHEMBL2199582

NC(=O)Nc1[nH]c(-c2ccc(Nc3ccc(N)cc3)cc2)cc1C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.40
CDC7 O00311 10/20 0.40
MAPT P10636 2/20 0.40
GAA P10253 1/20 0.40
GFER P55789 1/20 0.40
CDK2 P24941 2/20 0.39
CDK1 P06493 1/20 0.39
GAK O14976 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
FLT3 P36888 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
MARK1 Q9P0L2 1/20 0.38
STK17A Q9UEE5 1/20 0.38
CSF1R P07333 1/20 0.38
PRMT5 O14744 1/20 0.38
PRMT3 O60678 1/20 0.38
CARM1 Q86X55 1/20 0.38
EHMT2 Q96KQ7 1/20 0.38
PRMT6 Q96LA8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201619 0.93 BRD4 (0.45) BRD4CDC7CDK2CCNA2CCNA1
SCHEMBL4351557 0.84 BRD4 (0.46) BRD4MAPTGAA
SCHEMBL4351563 0.81 BRD4 (0.60) BRD4MAPTGAAGFERRAB9A
SCHEMBL12423887 0.80 BRD4 (0.59) BRD4CDC7CDK2CCNA2CCNA1
SCHEMBL2198026 0.80 CDC7 (0.57) BRD4CDC7CDK2CDK1CCNA2
SCHEMBL2197274 0.80 CDC7 (0.57) BRD4CDC7GAKPDGFRBKIT
SCHEMBL12509725 0.80 BRD4 (0.44) BRD4CDC7CDK2CCNA2CCNA1
SCHEMBL2198095 0.80 CDC7 (0.57) BRD4CDC7PDGFRBKITCSF1R
SCHEMBL2198480 0.80 NPC1 (0.46) BRD4CDC7CDK2RAB9ACCNA2
SCHEMBL2200146 0.80 BRD4 (0.62) BRD4CDC7CDK2CDK1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977371-B2 Pyrrole derivative having ureido group and aminocarbonyl group as substituents SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-07-12 US disclosed
US-20100099675-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-04-22 US disclosed
EP-2116530-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDE GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS Santen Pharmaceutical Co., Ltd (JP) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099675-A1 NOVEL PYRROLE DERIVATIVE HAVING UREIDO GROUP AND AMINOCARBONYL GROUP AS SUBSTITUENTS UACA, IL6, IL6ST BRD4 497/4885CDC7 4329/4885MAPT 3737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.